This is a partial list of the current clinical trials for new medications. If you are interested in finding more information, we’ve provided links to each study. You can also check the NIH National Library of Medicine clinicaltrials.gov to search for a more complete list and the status of each study.
- Debiopharm: In an important new development Swiss-based Debiopharm entered a Phase 3 trial of a new Octreotide formulation. The company is currently recruiting patients for the study. Debio 4126 is a sustained-release formulation designed to improve the convenience of somatostatin analogue (SSA) therapy for the treatment of acromegaly. The clinical trial is testing a 3-month long-acting formulation of octreotide, a long-standing drug used to treat acromegaly. Approval of this new formulation would result in a substantial improvement in convenience and increase the available options acromegaly patients have to find the appropriate drug to treat their condition A way to help: The Oxtend™-03 Clinical Trial
- Crinetics Pharmaceuticals moves forward with Atumelnant phase 3 study. More on this soon, but check clinicaltrials.gov
Other developments
- Camurus AB announced two clinical trials for an octreotide subcutaneous depot to treat acromegaly. Read more he…
- From Recordati Rare Diseases more news on its new drug for Cushing’s ISTURISA. Read more…
- Corcept Therapeutics launches website supporting Phase 3 Trial of Relacolirant in patients with Cushing’s syndrome. Click here to learn more and see if you qualify.
- Ionis Ph is currently enrolling acromegaly patients – more info at patients@ionisph.com
Please get in touch with us if you would like us to add a study to this list, and always check with your doctor for advice.
© 2022 – 2026, J D Faccinetti. All rights reserved.